5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• 5-Hydroxytryptamine3-receptor antagonists (5-HT3-RAs) are widely used antiemetics in cancer care.
• While generally well-tolerated, some 5-HT3-RAs have been linked to QTc prolongation, a cardiac adverse event.

Purpose of the Study:

• To review the risk of cardiac adverse events associated with 5-HT3-RAs.
• Focus on three common agents: ondansetron, granisetron, and palonosetron.

Main Methods:

• Review of existing literature on 5-HT3-RA use and cardiac events.
• Analysis of electrocardiogram (ECG) changes in various patient populations.

Main Results:

• Most studies focus on healthy young adults or non-cancer patients for postoperative nausea and vomiting (PONV).
• Limited data exists on ECG changes in cancer patients receiving 5-HT3-RAs for chemotherapy-induced nausea and vomiting (CINV).

Conclusions:

• Cancer patients often have comorbidities and polypharmacy, increasing cardiac risks.
• Future research must address cardiac adverse events in cancer patients, particularly older adults with pre-existing heart conditions, receiving 5-HT3-RAs for CINV prophylaxis.